Mira Pharmaceuticals
Mira Pharmaceuticals is a clinical-stage pharmaceutical company developing three novel oral drug candidates — Ketamir-2 (NMDA modulator for neuropathic pain), MIRA-55 (cannabinoid analog for anxiety and pain), and SKNY-1 (endocannabinoid modulator for obesity and addiction) — targeting large unmet needs in neurologic, neuropsychiatric, and metabolic disorders, with no product revenue yet.
- Company typePublic
- Founded2022
- HeadquartersBaltimore, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mira Pharmaceuticals does
Mira Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company incorporated in September 2020 and headquartered in Miami, Florida, developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The company operates with a headcount of 1-10 employees and has not yet generated revenue from product sales. Its pipeline consists of three distinct oral drug candidates: Ketamir-2, a low-affinity NMDA receptor antagonist and ketamine analog engineered for oral bioavailability and improved blood-brain barrier penetration (targeting neuropathic pain, chemotherapy-induced peripheral neuropathy (CIPN), treatment-resistant depression, MDD with suicidal ideation, and PTSD); MIRA-55, a non-psychotropic cannabinoid analog designed for selective CB2 activation with minimized CB1 binding (targeting anxiety, cognitive decline associated with early-stage dementia, and inflammatory pain); and SKNY-1, a multi-pathway endocannabinoid modulator combining biased CB1 antagonism, CB2 partial agonism, and mild MAO-B inhibition (targeting obesity and nicotine addiction, acquired through the September 2025 SKNY Pharmaceuticals acquisition).
The company's underlying technology is proprietary medicinal chemistry rather than a software platform: each candidate is a patent-pending novel molecular entity positioned against receptor targets (NMDA, CB1/CB2, MAO-B) where existing therapies have meaningful limitations such as opioid risk, sedation, addiction, or injection-only administration. Mira has secured regulatory advantages including DEA determination that both Ketamir-2 and MIRA-55 are not controlled substances, and FDA IND clearance for Ketamir-2 in neuropathic pain. Preclinical data points to 112% greater efficacy than pregabalin and 100% reversal of nerve-ligation neuropathic pain for Ketamir-2, morphine-comparable anti-inflammatory efficacy for oral MIRA-55, and up to 30% weight loss with muscle preservation for SKNY-1.
Mira's business model is pre-commercial pharmaceutical development: revenue is expected to come from product sales upon FDA approval, with future distribution planned through traditional pharmaceutical wholesale and specialty pharmacy channels. The company currently monetizes only through capital markets activity, having been valued at approximately $68.26 million as of December 2025 with a stock price of $1.63. Customer segments are defined by indication (CIPN patients, neuropathic pain patients, anxiety and cognitive decline patients, obesity and smoking cessation patients, inflammatory pain patients) rather than enterprise buyers, and the company is currently preparing for Phase 2a clinical trials rather than commercial launch. Operating geographies served are the USA, Canada, and Mexico, with clinical operations extending to Israel and the Netherlands.
Mira Pharmaceuticals firmographics
Firmographics- Name
- Mira Pharmaceuticals
- Legal name
- MIRA Pharmaceuticals, Inc.
- Website
- https://mirapharmaceuticals.com
- Company type
- Public
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Mira Pharmaceuticals is a clinical-stage pharmaceutical company developing three novel oral drug candidates — Ketamir-2 (NMDA modulator for neuropathic pain), MIRA-55 (cannabinoid analog for anxiety and pain), and SKNY-1 (endocannabinoid modulator for obesity and addiction) — targeting large unmet needs in neurologic, neuropsychiatric, and metabolic disorders, with no product revenue yet.
- Ownership category
- akta.pro rank
Mira Pharmaceuticals industry classification
Industry- Product category
- Clinical-Stage Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Mira Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Baltimore
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Mira Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Drug Development and Commercialization: Mira Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The company has not yet generated revenue from product sales as all drug candidates are in preclinical or clinical development stages. Future revenue will come from product sales upon FDA approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Mira Pharmaceuticals product offering
Product offeringCore offering
Mira Pharmaceuticals is a clinical-stage pharmaceutical company developing and commercializing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders. Its pipeline consists of three proprietary drug candidates: Ketamir-2 (an oral NMDA receptor modulator/ketamine analog for neuropathic pain and CIPN), MIRA-55 (a non-psychotropic cannabinoid analog for anxiety and inflammatory pain), and SKNY-1 (an endocannabinoid modulator for obesity and nicotine addiction). All three candidates have received DEA determination as non-controlled substances and are progressing through preclinical and Phase 1/2a clinical development toward potential FDA approval and commercialization.
Product overview
Mira Pharmaceuticals is a clinical-stage pharmaceutical company developing a portfolio of novel oral therapeutics targeting neurologic, neuropsychiatric, and metabolic disorders. The company's pipeline consists of three distinct drug candidates: Ketamir-2 (an NMDA receptor modulator for neuropathic pain and central nervous system disorders), MIRA-55 (a cannabinoid analog for anxiety and cognitive decline), and SKNY-1 (an endocannabinoid modulator for obesity and addiction). All three candidates have received DEA determination as non-controlled substances, supporting their development as non-scheduled therapeutic options.
Differentiator
Problem solved
Functional benefit
Products and services
- Ketamir-2 A novel oral NMDA receptor modulator (ketamine analog) being developed for the treatment of neuropathic pain, chemotherapy-induced peripheral neuropathy (CIPN), treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. The drug has received DEA determination as a non-controlled substance and is currently advancing through Phase 2a clinical trials.
- MIRA-55 A novel oral pharmaceutical marijuana analog targeting cannabinoid receptors CB1 and CB2, being developed for anxiety, cognitive decline associated with early-stage dementia, and chronic inflammatory pain. The compound is engineered to provide therapeutic benefits without the psychotropic side effects of THC, with DEA determination as a non-controlled substance.
- SKNY-1 An oral drug candidate targeting the endocannabinoid system for the treatment of obesity and nicotine addiction. The compound utilizes a multi-pathway approach including biased CB1 antagonism, CB2 partial agonism, and mild MAO-B inhibition, designed to avoid CNS side effects seen with earlier CB1-targeting drugs.
Quantifiable outcome
- Ketamir-2 achieved 60% greater efficacy than gabapentin and 112% greater than pregabalin in preclinical neuropathic pain models
- +4 more outcomes
Companies that use Mira Pharmaceuticals
Customer profileSegments5 records
Ideal customer profiles2 records
Mira Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Mira Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- RecipharmcoreRecipharm provides critical manufacturing and development support for Mira Pharmaceuticals' drug development programs including GMP preparation for Telomir-1 and Ketamir-2 Phase 1 SAD testing. The partnership supports manufacturing and development advances across clinical programs.
- PharmaseedcoreResearch partner conducting preclinical behavioral assays and studies for Mira-55 including validated behavioral tests at doses of 10, 30, and 100 mg/kg oral administration. Partnership enables testing for sedation, catalepsy, motor impairment, and anxiety-like effects.
- FormulexcoreCollaboration on spray-dry based granulation of Ketamir-2 in capsules for clinical studies, optimizing formulation for improved oral bioavailability and patient convenience. Drug product development partnership for novel oral ketamine analog capsules.
- Centre for Human Drug Research (CHDR)coreSelected as clinical trial site in Leiden, The Netherlands for Phase I/IIa trials. Utilizes proprietary PainCart technology for measuring pain response, allowing early efficacy assessment in healthy subjects. Trial design enables robust early proof-of-concept data.
- SKNY PharmaceuticalscoreAcquisition completed adding SKNY-1 drug candidate to pipeline. Transaction included $5 million capital infusion and brought obesity and smoking cessation drug candidate into MIRA's portfolio. Represents transformative pipeline expansion.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Mira Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Corbus Pharmaceuticals: Clinical-stage pharmaceutical company developing cannabinoid-derived therapeutics for inflammatory and fibrotic diseases. Comparable mechanism class and clinical-development stage to MIRA's endocannabinoid modulators.
- Zynerba Pharmaceuticals: Clinical-stage specialty pharmaceutical company developing transdermal cannabinoid therapeutics for neuropsychiatric conditions including Fragile X syndrome and epilepsy. Overlaps with MIRA's cannabinoid analog approach.
- Compass Pathways: Clinical-stage mental health care company developing psilocybin-based therapies for treatment-resistant depression. Comparable to MIRA's strategy of repurposing controlled-substance-class chemistry into differentiated, mainstream-positioned therapeutics.
- Atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and cannabinoid-derived therapeutics for mental health indications. Closely comparable to MIRA's MIRA-55 strategy of engineering non-psychotropic cannabinoid analogs.
- Tonix Pharmaceuticals: Clinical-stage CNS-focused pharmaceutical company developing therapeutics for pain, PTSD, depression, and fibromyalgia. Direct comparable to MIRA's Ketamir-2 program targeting neuropathic pain and CNS indications.
- Tetra Bio-Pharma: Clinical-stage cannabinoid-derived pharmaceutical company developing novel treatments for pain and inflammatory conditions. Direct overlap with MIRA's MIRA-55 program targeting chronic inflammatory pain.
Emerging players
- Voyager Therapeutics: Clinical-stage gene therapy company developing CNS-targeted therapeutics for neurological diseases. Comparable clinical-stage risk profile and small-cap public-company dynamics to MIRA.
- PharmaTher: Specialty pharmaceutical company focused on ketamine-based therapeutics for neurological and mental health disorders. Closely comparable to MIRA's Ketamir-2 program targeting NMDA receptor modulation.
Broad incumbents
- Axsome Therapeutics: Commercial-stage CNS biopharmaceutical company with approved products in major depressive disorder and migraine. Overlaps with MIRA's CNS/neuropathic pain focus and represents the scaled-up commercial trajectory MIRA is pursuing.
- Sage Therapeutics: CNS-focused biopharmaceutical company with FDA-approved therapy for postpartum depression and a pipeline in major depressive disorder. Comparable regulatory and clinical-development pathway for novel neuro-active compounds.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Mira Pharmaceuticals social profiles
Digital presenceMira Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mira Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles4 records
Mira Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
Mira Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mira Pharmaceuticals M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mira Pharmaceuticals
What does Mira Pharmaceuticals do?
Mira Pharmaceuticals is a clinical-stage pharmaceutical company developing and commercializing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders. Its pipeline consists of three proprietary drug candidates: Ketamir-2 (an oral NMDA receptor modulator/ketamine analog for neuropathic pain and CIPN), MIRA-55 (a non-psychotropic cannabinoid analog for anxiety and inflammatory pain), and SKNY-1 (an endocannabinoid modulator for obesity and nicotine addiction). All three candidates have received DEA determination as non-controlled substances and are progressing through preclinical and Phase 1/2a clinical development toward potential FDA approval and commercialization.
Is Mira Pharmaceuticals a public or private company?
Mira Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Mira Pharmaceuticals founded?
Mira Pharmaceuticals was founded in 2022. It employs 1 to 10 people.
Where is Mira Pharmaceuticals based?
Mira Pharmaceuticals is headquartered in Baltimore, United States, in the North America region.
How does Mira Pharmaceuticals make money?
One revenue line is on record: pharmaceutical Drug Development and Commercialization.
Who are Mira Pharmaceuticals's main competitors?
Direct peers on record are Corbus Pharmaceuticals, Zynerba Pharmaceuticals, Compass Pathways, Atai Life Sciences, Tonix Pharmaceuticals and Tetra Bio-Pharma. Emerging players are Voyager Therapeutics and PharmaTher. Broad incumbents are Axsome Therapeutics and Sage Therapeutics.
Does Mira Pharmaceuticals have an API?
No public API is recorded for Mira Pharmaceuticals.
What industry is Mira Pharmaceuticals in?
Mira Pharmaceuticals's product category is Clinical-Stage Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.